Clinical Trial Update: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine

View source ↗

Summary

The document reports results from a French temporary utilization authorization study of first-line acute myeloid leukemia patients ineligible for intensive chem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: AML, Adult | Status: RECRUITING